• Xiaoning He, Mengqian Zhang, Jing Wu, Song Xu, Xiangli Jiang, Ziping Wang, Shucai Zhang, and Feng Xie.
• School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People's Republic of China.
• Patient Prefer Adher. 2021 Jan 1; 15: 775783775-783.

BackgroundCancer treatment decision-making often needs to balance benefits, harms, and costs. This study sought to identify the differences in cancer treatment preference among oncologists, patients and their family members in China.MethodsA semi-structured face-to-face qualitative interview was conducted among oncologists, patients and their family members recruited in four tertiary hospitals in China. The interview guide was developed based on literature review and expert consultation. Participants were asked to indicate their preferences when making lung cancer treatment decisions. All interviews were audio-taped, transcribed verbatim, and thematic analyzed. The preferences were compared among three groups of participants.ResultsA total of 17 participants (5 oncologists, 6 dyads of patients and family members) were interviewed between June and July 2019. Five themes, namely, survival benefit, adverse effect/symptom, treatment process, treatment cost, and the impact on daily life were identified. The oncologists and family members gave highest priority on survival benefit, while the patients are concerned most about treatment cost and quality of life.ConclusionThis study reveals different preferences for cancer treatment among oncologists, patients and their family members in China. Education is needed to empower patients and family members and promote share decision-making in this country.© 2021 He et al.

5 keywords...

hide…